Purple Biotech Statistics

Total Valuation

Purple Biotech has a market cap or net worth of $8.87 million. The enterprise value is $2.62 million.

Market Cap	8.87M
Enterprise Value	2.62M

Important Dates

The next estimated earnings date is Tuesday, March 4, 2025, before market open.

Earnings Date	Mar 4, 2025
Ex-Dividend Date	n/a

Share Statistics

Purple Biotech has 1.73 million shares outstanding. The number of shares has increased by 9.34% in one year.

Current Share Class	n/a
Shares Outstanding	1.73M
Shares Change (YoY)	+9.34%
Shares Change (QoQ)	-99.37%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	469.95M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
Forward PS	n/a
PB Ratio	n/a
P/TBV Ratio	5.65
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 1.27, with a Debt / Equity ratio of 0.01.

Current Ratio	1.27
Quick Ratio	1.15
Debt / Equity	0.01
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	-29.08

Financial Efficiency

Return on equity (ROE) is -34.39% and return on invested capital (ROIC) is -29.18%.

Return on Equity (ROE)	-34.39%
Return on Assets (ROA)	-24.97%
Return on Invested Capital (ROIC)	-29.18%
Return on Capital Employed (ROCE)	-54.15%
Revenue Per Employee	n/a
Profits Per Employee	-$582,900
Employee Count	20
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -74.96% in the last 52 weeks. The beta is 0.38, so Purple Biotech's price volatility has been lower than the market average.

Beta (5Y)	0.38
52-Week Price Change	-74.96%
50-Day Moving Average	3.82
200-Day Moving Average	6.93
Relative Strength Index (RSI)	39.64
Average Volume (20 Days)	51,073

Short Selling Information

Short Interest	100,377
Short Previous Month	141,624
Short % of Shares Out	1.33%
Short % of Float	n/a
Short Ratio (days to cover)	0.43

Income Statement

Revenue	n/a
Gross Profit	-196,000
Operating Income	-16.05M
Pretax Income	18.76M
Net Income	-11.66M
EBITDA	-16.01M
EBIT	-16.05M
Earnings Per Share (EPS)	-$0.05

Full Income Statement

Balance Sheet

The company has $6.30 million in cash and $222,000 in debt, giving a net cash position of $6.08 million or $3.51 per share.

Cash & Cash Equivalents	6.30M
Total Debt	222,000
Net Cash	6.08M
Net Cash Per Share	$3.51
Equity (Book Value)	29.47M
Book Value Per Share	16.98
Working Capital	1.48M

Full Balance Sheet

Cash Flow

Operating Cash Flow	-17.34M
Capital Expenditures	n/a
Free Cash Flow	-17.34M
FCF Per Share	-$10.01

Full Cash Flow Statement

Margins

Gross Margin	n/a
Operating Margin	n/a
Pretax Margin	n/a
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Purple Biotech does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-9.34%
Shareholder Yield	-9.34%
Earnings Yield	-131.42%
FCF Yield	-195.42%

Analyst Forecast

The average price target for Purple Biotech is $126.50, which is 3,792.31% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$126.50
Price Target Difference	3,792.31%
Analyst Consensus	Strong Buy
Analyst Count	2
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	n/a

Stock Forecasts

Stock Splits

The last stock split was on September 17, 2024. It was a reverse split with a ratio of 0.05:1.

Last Split Date	Sep 17, 2024
Split Type	Reverse
Split Ratio	0.05:1

Scores

Altman Z-Score	n/a
Piotroski F-Score	n/a